Biopharmaceutical company Oncobiologics, Inc. recently announced that its product ONS-3010, an adalimumab (Humira®) biosimilar candidate, has met the primary endpoints in its first clinical trial. ONS-3010 was developed as a biosimilar of adalimumab, ... Read more